CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 27 enrolled
Drug / intervention
atomoxetine +1 moredrug
Likely dose
atomoxetine 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00260533
NCT00260533Phase 3Completed
CompareCT.gov

Double Blind Placebo Controlled Parallel Group Comparison of Atomoxetine (Strattera) for Generalized Social Anxiety Disorder (GSAD)

University of California, San Diego·interventional·Posted Dec 1, 2005·Updated Jun 24, 2016

In Brief

A Phase 3 clinical trial evaluating atomoxetine and placebo for Generalized Social Phobia. Completed, enrolled 27 participants.

Detailed Summary

The purpose of this study is to determine the effectiveness and tolerability of atomoxetine (Strattera) in adult patients with generalized social anxiety disorder (an anxiety disorder characterized by a fear of interpersonal interactions).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGeneralized Social Phobia
Countries--
CollaboratorsEli Lilly and Company

Timeline

Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 1, 2005
Enrollment StartNov 1, 2005
Primary CompletionJul 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 20.6 years ago

Interventions

atomoxetinedrug

Flexible dose, up to 50 mg per day

placebodrug

placebo (matching to atomoxetine)